TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma

European Journal of Endocrinology

Volumn 172, Issue 4, 2015, Pages 403-413

  Gandolfi, Greta ^a   Ragazzi, Moira ^a   Frasoldati, Andrea ^a   Piana, Simonetta ^a   Ciarrocchi, Alessia ^a   Sancisi, Valentina ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE; TERT PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFERENTIATED THYROID CANCER; DIRECT SANGER SEQUENCING; DISTANT METASTASIS; FEMALE; FOLLOW UP; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; TERT GENE; ADOLESCENT; CARCINOMA; CASE CONTROL STUDY; GENETICS; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TELOMERASE; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84927637308     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0837     Document Type: Article

References (40)

1. Davies L & Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. Journal of the American Medical Association 2006 295 2164-2167. (doi:10.1001/jama.295.18.2164)
2. Pellegriti G, Frasca F, Regalbuto C, Squatrito S & Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. Journal of Cancer Epidemiology 2013 2013 965212. (doi:10.1155/2013/965212)
3. Davies L & Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngology - Head & Neck Surgery 2014 140 317-322. (doi:10.1001/jamaoto.2014.1)
4. Kondo T, Ezzat S & Asa S. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews. Cancer 2006 6 292-306. (doi:10.1038/nrc1836)
5. Handkiewicz-Junak D, Czarniecka A & Jarzab B. Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Molecular and Cellular Endocrinology 2010 322 8-28. (doi:10.1016/j.mce.2010.01.007)
6. Haq M & Harmer C. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clinical Endocrinology 2005 63 87-93. (doi:10.1111/j.1365-2265.2005.02304.x)
7. Li C, Lee KC, Schneider EB & Zeiger MA. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2012 97 4559-4570. (doi:10.1210/jc.2012-2104)
8. Hanahan D & Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011 144 646-674. (doi:10.1016/j.cell.2011.02.013)
9. Greider CW & Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985 43 405-413. (doi:10.1016/0092-8674(85)90170-9)
10. Collins K. The biogenesis and regulation of telomerase holoenzymes. Nature Reviews. Molecular Cell Biology 2006 7 484-494. (doi:10.1038/nrm1961)
11. Harley CB. Telomerase and cancer therapeutics. Nature Reviews. Cancer 2008 8 167-179. (doi:10.1038/nrc2275)
12. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013 339 959-961. (doi:10.1126/science.1230062)
13. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L & Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science 2013 339 957-959. (doi:10.1126/science.1229259)
14. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. PNAS 2013 110 6021-6026. (doi:10.1073/pnas.1303607110)
15. Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T, Allaf M, Springer S, Wang Y, Diaz LA et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Research 2013 73 7162-7167. (doi:10.1158/0008-5472.CAN-13-2498)
16. Liu X, Wu G, Shan Y, Hartmann C, von Deimling A & Xing M. Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle 2013 12 1637-1638. (doi:10.4161/cc.24662)
17. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C & Zucman-Rossi J. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nature Communications 2013 4 2218. (doi:10.1038/ncomms3218)
18. Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, Wiklund NP, Steineck G, Schadendorf D, Hemminki K et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. PNAS 2013 110 17426-17431. (doi:10.1073/pnas.1310522110)
19. Tallet A, Nault JC, Renier A, Hysi I, Galateau-Salle F, Cazes A, Copin MC, Hofman P, Andujar P, Le Pimpec-Barthes F et al. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene 2013 33 3748-3752. (doi:10.1038/onc.2013.351)
20. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L et al. Frequency of TERT promoter mutations in human cancers. Nature Communications 2013 4 2185. (doi:10.1038/ncomms3185)
21. Heidenreich B, Nagore E, Rachakonda PS, Garcia-Casado Z, Requena C, Traves V, Becker J, Soufir N, Hemminki K & Kumar R. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nature Communications 2014 5 3401. (doi:10.1038/ncomms4401)
22. Wu RC, Ayhan A, Maeda D, Kim KR, Clarke BA, Shaw P, Chui MH, Rosen B, Shih Ie M & Wang TL. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. Journal of Pathology 2014 232 473-481. (doi:10.1002/path.4315)
23. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA & Fagin JA. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. Journal of Clinical Endocrinology and Metabolism 2013 98 E1562-E1566. (doi:10.1210/jc.2013-2383)
24. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK & Xing M. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-Related Cancer 2013 20 603-610. (doi:10.1530/ERC-13-0210)
25. Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C & Xu D. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 2014 33 4978-4984. (doi:10.1038/onc.2013.446)
26. Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2014 99 E1130-E1136. (doi:10.1210/jc.2013-4048)
27. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 2014 99 E754-E765. (doi:10.1210/jc.2013-3734)
28. Vinagre J, Pinto V, Celestino R, Reis M, Pópulo H, Boaventura P, Melo M, Catarino T, Lima J, Lopes JM et al. Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Archiv 2014 465 119-133. (doi:10.1007/s00428-014-1608-4)
29. De Lellis RA, Lloyd RV, Heitz PU & Eng C. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumors of Endocrine Organs, 1st edn, Lyon, France: IARC Press, 2004.
30. Edge SB, Compton CC & Fritz AG. In AJCC Cancer Staging Manual, 7th edn, New York: Springer, 2010.
31. Sancisi V, Nicoli D, Ragazzi M, Piana S & Ciarrocchi A. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. Journal of Clinical Endocrinology and Metabolism 2012 97 E1745-E1749. (doi:10.1210/jc.2012-1526)
32. Gandolfi G, Sancisi V, Torricelli F, Ragazzi M, Frasoldati A, Piana S & Ciarrocchi A. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. Journal of Clinical Endocrinology and Metabolism 2013 98 E934-E942. (doi:10.1210/jc.2012-3930)
33. Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S & Bishop J. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. Journal of Clinical Oncology 2014 32 2718-2726. (doi:10.1200/JCO.2014.55.5094)
34. Esserman LJ, Thompson IM Jr & Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. Journal of the American Medical Association 2013 310 797-798. (doi:10.1001/jama.2013.108415)
35. Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathologica 2013 126 267-276. (doi:10.1007/s00401-013-1141-6)
36. Del Bufalo D, Rizzo A, Trisciuoglio D, Cardinali G, Torrisi MR, Zangemeister-Wittke U, Zupi G & Biroccio A. Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function. Cell Death and Differentiation 2005 12 1429-1438. (doi:10.1038/sj.cdd.4401670)
37. Masutomi K, Possemato R, Wong JM, Currier JL, Tothova Z, Manola JB, Ganesan S, Lansdorp PM, Collins K & Hahn WC. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. PNAS 2005 102 8222-8227. (doi:10.1073/pnas.0503095102)
38. Rahman R, Latonen L & Wiman KG. hTERT antagonizes p53-induced apoptosis independently of telomerase activity. Oncogene 2005 24 1320-1327. (doi:10.1038/sj.onc.1208232)
39. Calado RT & Chen J. Telomerase: not just for the elongation of telomeres. BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology 2006 28 109-112. (doi:10.1002/bies.20365)
40. Parkinson EK, Fitchett C & Cereser B. Dissecting the non-canonical functions of telomerase. Cytogenetic and Genome Research 2008 122 273-280. (doi:10.1159/000167813)